Consistent Q2 growth for the world’s largest CRO (contract research organization) Quintiles was driven by a spike in the company’s Integrated Healthcare Services (IHS) segment.
A breakdown of trials run by the top contract research organizations (CROs) reveals that the big players are leaving little room for smaller firm to compete, according to a review by Outsourcing-Pharma.com of trials in clinicaltrials.gov.
Last week Quintiles gave Outsourcing-Pharma a tour of its headquarters and offered an inside look at some of its latest developing technology and thought leadership.
Negotiating funding for drugs with local health authorities prior to commercialisation is the key to success for biopharmas working in the changing European market, says Quintiles.
US CRO Quintiles has postponed a financing plan it announced earlier this month, citing unfavourable global credit market conditions as the reason for the decision.
Quintiles is continuing to build alliances with large pharmas, inking deals to perform “the majority” of AstraZeneca’s (AZ) clinical pharmacology work and develop six oncology products in Eisai’s pipeline.
Quintiles believes there is a “dire need” for trial sites that can raise standards and reduce inefficiencies in the clinical research process and is expanding its Prime Site programme to meet this demand.
Quintiles Transnational has heralded the results of an
independently conducted study of clinical investigator sites across
Europe that saw the firm rate the highest overall in terms of
satisfaction.
Outsourcing-Pharma.com compiles the news that has featured in the
clinical contract community of late, involving Global Research
Services, Quintiles and Icon.
Quintiles Transnational has launched a new screening technology for
drug discovery and development to detect the interaction of
compounds with ion channels.